Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Jazz Pharmaceuticals PLC JAZZ
News
-
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
Jazz Pharmaceuticals Focuses on Taking Actions To Positively Impact the Planet This Earth Month
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
Cancer and the Combination Approach
Jazz Pharmaceuticals Celebrates International Women’s Day
Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals
How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program